How Long Can You Stay on Hormone Therapy? What Current Guidance Actually Says
Last updated: July 2026
A patient on hormone therapy for six years asked me recently whether she was "supposed to have stopped by now." She'd heard somewhere that five years was the ceiling. She wasn't having new symptoms. Her labs looked fine. She just assumed there was a clock running out on her prescription, and that continuing past it meant she was doing something wrong.
She isn't the only one carrying that assumption. The "five-year rule" has circulated for two decades, and it has outlived the evidence that ever loosely supported it. This post walks through where that number came from, what the current guidance actually says about duration, and why the right question isn't "when do I stop" but "does this still make sense for me, reassessed regularly."
Where the Five-Year Rule Came From
The number traces back to the Women's Health Initiative (WHI), the large federal study published in 2002 that linked combined hormone therapy to increased risk of breast cancer, stroke, and blood clots. The findings were alarming enough, and reported widely enough, that an entire generation of physicians was trained to treat hormone therapy as something to prescribe briefly and taper off quickly. Five years became a kind of informal ceiling, repeated so often it hardened into a rule that was never actually a rule.
What got lost in that reaction:
The WHI population skewed older, with an average participant age of 63, many years past the onset of menopause.
The formulation studied, oral conjugated equine estrogen with medroxyprogesterone acetate, is not the formulation most commonly prescribed today.
Later reanalysis of the same WHI data showed a very different risk picture for women who started therapy younger and closer to menopause onset.
That reanalysis is a big part of why the guidance has changed so substantially since 2002, and why the FDA itself has recently revised how it labels these medications.
What Current Guidance Actually Says
The Menopause Society's 2022 position statement, still the primary clinical reference in this space, does not set a fixed number of years for stopping hormone therapy. Instead, it recommends individualized treatment based on the best available evidence, with periodic reevaluation of the benefits and risks of continuing therapy. For women who are younger than 60 or within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is described as favorable for treatment of bothersome vasomotor symptoms and prevention of bone loss. Longer durations aren't discouraged outright. The guidance is explicit that longer durations of therapy should be supported by documented indications, shared decision-making, and periodic reevaluation, not by an arbitrary calendar.
This isn't a fringe reading of the evidence. A more recent Menopause Society analysis found that it isn't unusual for women as old as 80 to still benefit from hormone therapy with appropriate counseling and risk assessment, and the organization has stated there is no strict age limit built into current recommendations, provided ongoing counseling and risk assessment continue.
The regulatory picture has moved in the same direction. In November 2025, the FDA requested that manufacturers remove the black box warning language tied to cardiovascular disease, breast cancer, and probable dementia from most estrogen-containing hormone therapy products, concluding that the original warnings no longer reflected how these products are prescribed and used in current practice. The endometrial cancer warning for estrogen-alone products in women with a uterus remains in place, which is a distinction worth understanding rather than a reason for alarm. ACOG's own clinical guidance echoes the same principle: regardless of a woman's age, the choice to continue hormone therapy should be individualized and based on symptoms and the risk-to-benefit ratio, not on how many years have passed since she started.
Why Duration Isn't the Right Question
I understand the appeal of a fixed rule. A number feels safer than a judgment call. But menopause physiology doesn't work on a timer, and neither does risk.
A few things actually determine whether continuing hormone therapy makes sense for a given patient:
How close she was to menopause onset when she started therapy, since risk profiles differ meaningfully between women who begin within 10 years of onset and those who start later
Which formulation and route she's using, since transdermal estrogen carries a different risk profile than oral formulations
Whether her symptoms, particularly vasomotor symptoms and genitourinary symptoms, are still present and still bothersome
Her personal and family history, including any changes since she started treatment
Whether she has a uterus, which changes the calculus around progestogen and endometrial protection
None of that changes on a five-year schedule. It changes as her life and her body change, which is exactly why it needs to be looked at regularly rather than decided once and left alone.
What Annual Reassessment Looks Like in Practice
I use the term "annual reassessment" deliberately, instead of a stop date, because that's a more accurate description of what good hormone therapy management actually requires. Each year, we revisit:
Whether her symptoms have changed, improved, or resolved
Whether new health information (a family diagnosis, a new medication, a change in blood pressure or lipids) shifts her individual risk profile
Whether the formulation, dose, or route still makes sense or should be adjusted
Whether she still wants to continue, because her preference matters as much as the clinical picture
This is where a longitudinal care relationship changes the equation. Reassessment only works if someone actually knows the patient's baseline and has the time to track it year over year, rather than reviewing a chart cold for fifteen minutes. That kind of continuity is a structural feature of how I practice, and it's part of why I can have this conversation with the specificity it deserves. For patients working through the broader hormonal timeline, our post on the perimenopause and menopause timeline is a useful companion to this one, since duration decisions only make sense in the context of where a patient actually is in that process.
A Patient Example
Consider a patient, I'll call her a 54-year-old professional, who started transdermal estrogen and micronized progesterone at 49 for hot flashes and disrupted sleep. Five years in, she was doing well and had no new risk factors. Rather than tapering her off because of an informal timeline, we reviewed her most recent labs, discussed her family history since her last visit, and confirmed her symptoms would very likely return if she stopped. We continued therapy, with a plan to revisit again in a year. That's a fundamentally different process than the one built around an arbitrary stop date, and it's the process current guidance actually supports.
Cardiovascular risk is one of the factors that deserves particular attention in these annual conversations, since the protective effect of estrogen shifts during this window. Our post on heart health in midlife goes deeper into what that means for screening.
The Conversation That Should Replace the Stop Date
If you've been told, or have simply assumed, that you're supposed to stop hormone therapy after a set number of years, that assumption is worth revisiting with your physician, not with a calendar. The current evidence supports individualized decisions built on your specific history, your current symptoms, and regular reassessment, not a fixed endpoint that was never well supported to begin with.
This is also where credentials matter. A Menopause Society Certified Practitioner has demonstrated specific competency in exactly this kind of nuanced, ongoing decision-making, which is different from general familiarity with hormone therapy. If you're evaluating who should be guiding this conversation, our post on what MSCP certification actually means explains what that credential requires and why it's relevant here. You can also read more about how longer, unrushed visits change what this kind of care actually looks like in practice in our post about menopause care without the rush.
If you're due for that reassessment, or you've never had one, Premier Medicine and Wellness in Horsham, PA can be reached at 267-207-3100 to schedule a visit.
